At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 31 enrolled
Drug / intervention
Alisertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2 Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in the Treatment of Patients With Platinum-Refractory or Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
In Brief
A Phase 2 clinical trial evaluating Alisertib for Ovarian Carcinoma. Completed, enrolled 31 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the anti-tumour activity of alisertib (MLN8237) in the treatment of participants with platinum-refractory or platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinomas.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Carcinoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 2009
Enrollment StartMar 2009
Primary CompletionNov 2009
Study CompletionJan 2011
TodayJul 2026
First PostedMar 2, 2009
Enrollment StartMar 23, 2009
Primary CompletionNov 23, 2009
Study CompletionJan 27, 2011
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 17.3 years ago
Interventions
Alisertibdrug
Alisertib capsules